TY - JOUR
T1 - Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
AU - Swan, Suzanne K.
AU - Rudy, David W.
AU - Lasseter, Kenneth C.
AU - Ryan, Charles F.
AU - Buechel, Kristin L.
AU - Lambrecht, Laurence J.
AU - Pinto, Manuel B.
AU - Dilzer, Stacy C.
AU - Obrda, Olga
AU - Sundblad, Kimberly J.
AU - Gumbs, Carol P.
AU - Ebel, David L.
AU - Quan, Hui
AU - Larson, Patrick J.
AU - Schwartz, Jules I.
AU - Musliner, Thomas A.
AU - Gertz, Barry J.
AU - Brater, D. Craig
AU - Yao, Siu Long
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2000/7/4
Y1 - 2000/7/4
N2 - Background: Most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1), whose inhibition is associated with gastrointestinal ulceration, and COX-2, whose inhibition is associated with therapeutic benefits. Although agents that do not produce COX-1 activity may have fewer adverse effects, targeted disruption of the COX-2 allele in mice has resulted in severe renal problems, suggesting that COX-2 inhibition may also produce adverse effects. Objective: To determine the effect of rofecoxib, a member of the coxib class of drugs and a specific inhibitor of the COX-2 enzyme, on renal function in elderly patients. Design: A randomized, three-period, single-dose crossover study and a randomized, parallel-group, multiple-dose study. Setting: Clinical research units. Patients: 75 patients 60 to 80 years of age. Intervention: In the first study, single doses of rofecoxib, 250 mg (about 5-fold to 20-fold the recommended dose); indomethacin, 75 mg; and placebo were administered to 15 patients. In the second study, multiple doses of rofecoxib, 12.5 or 25 mg/d; indomethacin, 50 mg three times daily; or placebo were administered to 60 patients. Patients in both studies received a low-sodium diet. Measurements: Glomerular filtration rate, creatinine clearance, and urinary and serum sodium and potassium values. Results: Compared with placebo, single doses of rofecoxib and indomethacin decreased the glomerular filtration rate by 0.23 mL/s (P < 0.001) and 0.18 mL/s (P = 0.003), respectively. In contrast, respective decreases of 0.14, 0.13, and 0.10 mL/s were observed after multiple doses of rofecoxib, 12.5 mg/d (P= 0.019); rofecoxib, 25 mg (P= 0.029), and indomethacin (P= 0.086) were administered. Changes in creatinine clearance and serum and urinary sodium and potassium were less pronounced. Conclusions: The effects of COX-2 inhibition on renal function are similar to those observed with nonselective NSAIDs. Thus, COX-2 seems to play an important role in human renal function.
AB - Background: Most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1), whose inhibition is associated with gastrointestinal ulceration, and COX-2, whose inhibition is associated with therapeutic benefits. Although agents that do not produce COX-1 activity may have fewer adverse effects, targeted disruption of the COX-2 allele in mice has resulted in severe renal problems, suggesting that COX-2 inhibition may also produce adverse effects. Objective: To determine the effect of rofecoxib, a member of the coxib class of drugs and a specific inhibitor of the COX-2 enzyme, on renal function in elderly patients. Design: A randomized, three-period, single-dose crossover study and a randomized, parallel-group, multiple-dose study. Setting: Clinical research units. Patients: 75 patients 60 to 80 years of age. Intervention: In the first study, single doses of rofecoxib, 250 mg (about 5-fold to 20-fold the recommended dose); indomethacin, 75 mg; and placebo were administered to 15 patients. In the second study, multiple doses of rofecoxib, 12.5 or 25 mg/d; indomethacin, 50 mg three times daily; or placebo were administered to 60 patients. Patients in both studies received a low-sodium diet. Measurements: Glomerular filtration rate, creatinine clearance, and urinary and serum sodium and potassium values. Results: Compared with placebo, single doses of rofecoxib and indomethacin decreased the glomerular filtration rate by 0.23 mL/s (P < 0.001) and 0.18 mL/s (P = 0.003), respectively. In contrast, respective decreases of 0.14, 0.13, and 0.10 mL/s were observed after multiple doses of rofecoxib, 12.5 mg/d (P= 0.019); rofecoxib, 25 mg (P= 0.029), and indomethacin (P= 0.086) were administered. Changes in creatinine clearance and serum and urinary sodium and potassium were less pronounced. Conclusions: The effects of COX-2 inhibition on renal function are similar to those observed with nonselective NSAIDs. Thus, COX-2 seems to play an important role in human renal function.
UR - http://www.scopus.com/inward/record.url?scp=0034604272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034604272&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-133-1-200007040-00002
DO - 10.7326/0003-4819-133-1-200007040-00002
M3 - Article
C2 - 10877734
AN - SCOPUS:0034604272
VL - 133
SP - 1
EP - 9
IS - 1
ER -